Leerink Partnrs Increases Earnings Estimates for Galapagos

Galapagos NV (NASDAQ:GLPG - Free Report) - Equities research analysts at Leerink Partnrs increased their FY2024 earnings per share estimates for shares of Galapagos in a research report issued to clients and investors on Sunday, December 8th. Leerink Partnrs analyst F. Khurshid now forecasts that the biotechnology company will earn ($0.47) per share for the year, up from their prior estimate of ($0.48). Leerink Partnrs has a "Hold" rating on the stock. The consensus estimate for Galapagos' current full-year earnings is $0.52 per share. Leerink Partnrs also issued estimates for Galapagos' Q1 2025 earnings at ($0.20) EPS, Q2 2025 earnings at ($0.20) EPS, Q3 2025 earnings at ($0.20) EPS, Q4 2025 earnings at ($0.20) EPS, FY2025 earnings at ($0.80) EPS and FY2026 earnings at ($1.72) EPS.

Several other research analysts have also recently commented on GLPG. Royal Bank of Canada reduced their target price on shares of Galapagos from $32.00 to $30.00 and set a "sector perform" rating for the company in a report on Friday, November 1st. Leerink Partners started coverage on Galapagos in a report on Monday, September 9th. They set a "market perform" rating and a $24.00 target price on the stock. Finally, Kepler Capital Markets downgraded Galapagos from a "hold" rating to a "reduce" rating in a research note on Wednesday, November 20th. Two analysts have rated the stock with a sell rating and six have given a hold rating to the stock. According to MarketBeat, Galapagos currently has a consensus rating of "Hold" and an average target price of $30.75.

Galapagos Stock Down 0.1 %

Galapagos stock traded down $0.03 during midday trading on Wednesday, reaching $27.18. The stock had a trading volume of 256,201 shares, compared to its average volume of 150,028. Galapagos has a 1-year low of $24.16 and a 1-year high of $42.46. The firm's fifty day simple moving average is $28.10 and its 200-day simple moving average is $27.39.

Institutional Trading of Galapagos

Several institutional investors and hedge funds have recently bought and sold shares of the business. Creative Planning bought a new stake in Galapagos in the 2nd quarter valued at $456,000. Crossmark Global Holdings Inc. acquired a new position in shares of Galapagos in the third quarter valued at $1,077,000. Signaturefd LLC raised its position in shares of Galapagos by 65.6% in the third quarter. Signaturefd LLC now owns 6,413 shares of the biotechnology company's stock valued at $185,000 after purchasing an additional 2,541 shares during the period. Headlands Technologies LLC boosted its holdings in shares of Galapagos by 56.7% during the 2nd quarter. Headlands Technologies LLC now owns 1,233 shares of the biotechnology company's stock worth $31,000 after buying an additional 446 shares during the period. Finally, Stonepine Capital Management LLC grew its stake in Galapagos by 23.2% in the 2nd quarter. Stonepine Capital Management LLC now owns 485,000 shares of the biotechnology company's stock valued at $12,018,000 after buying an additional 91,366 shares during the last quarter. Institutional investors own 32.46% of the company's stock.

About Galapagos

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.